B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.